Diabetes Self-Management Education
Joan K. Bardsley, MBA, RN, CDE, describes a joint position statement regarding implementation of diabetes self-management education.
Diabetes self-management education is an important aspect of diabetes care, and clinicians need to increase its use.
AADE, ADA and AND released position statement on when a patient should be referred for diabetes self-management education.
A systematic review of evidence may help answer question of whether DSME benefits patients with diabetes.
Results highlight importance of addressing psychological issues, behavior change strategies and more.
Hypoglycemia is a serious problem for those with diabetes, and clinicians must educate their patients about the risks.
The program was associated with decreased high-fat food consumption and increased physical activity.
DIAMOS program also linked to significant reduction in risk for incident major depression.
Peer education was linked to improved psychological status and self-management in patients with type 2 diabetes and emotional disorders.
Diabetes self-management education improves glucose control and patient satisfaction in the hospital setting.
Diabetes self-management education was deemed effective in improving HbA1c after 2 years.
Help patients direct their energy into positive behaviors to manage their diabetes.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Testosterone Prescribing Trends in the United States Between 2002 and 2016
- The Future of Food and Drug Regulation: Trump Administration Proposes Reorganization of FDA, USDA
- Popliteal Sciatic Nerve Block May Increase Time to First Opioid Request in Diabetic Peripheral Neuropathy
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Subclinical Hypothyroidism: Controversies in Testing and Treatment